BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

Core Insights - BioCardia, Inc. has elected Mr. Marvin Slosman to its Board of Directors effective December 2, 2025, following the departure of Dr. Richard Krasno who completed his term on the same date [1][3]. Group 1: Board Changes - Mr. Marvin Slosman brings extensive expertise in interventional cardiology and a strong track record in advancing medical technologies from concept to commercialization [2]. - Dr. Richard Krasno has been recognized for his significant contributions during his tenure, including guiding the company through key milestones such as the development of clinical evidence for CardiAMP cell therapy and the FDA approval of Morph DNA [3][4]. Group 2: Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases, with its main product platforms being CardiAMP and CardiALLO cell therapies [5]. - The company is currently developing three clinical stage product candidates, supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms [5].